News
Sarepta completes filing of casimersen to treat patients with Duchenne Muscular Dystrophy who have genetic mutations that are amenable to skipping exon 45 of the Duchenne gene.
Sarepta has completed the submission of a rolling NDA to the FDA seeking accelerated approval for casimersen (SRP-4045). Casimersen, a phosphorodiamidate morpholino oligomer (PMO), is engineered to treat patients with Duchenne Muscular Dystrophy who have genetic mutations that are amenable to skipping exon 45 of the Duchenne gene.
Condition: Duchenne Muscular Dystrophy
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.